Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo.

NCT04910438 | Unknown

• 1 other identifier: ANRS 12400 DepIST-H
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The DepIST-H study, funded by the French AIDS and Hepatitis Research Agency (ANRS), is to estimate prevalence (the number of cases over a given period of time) and incidence (the number of new cases over a given period of time) of anal lesions (condylomas, dysplasia, cancers) by HIV status among MSM in Lomé, Togo

Conditions

Papillomavirus Infections; HIV Infections

Keywords

HPV; HIV; MSM; Togo

Outcome Measures

Primary Outcomes (1)

• Prevalence at inclusion of anal lesions

  According to HIV status among MSM in Lomé, Togo

  at Day 0

Secondary Outcomes (8)

• Prevalence of anal lesions at baseline

  at Day 0

• Incidence of anal lesions

  at 12 month and 24 month

• Describe the number of worsening events of anal cytological lesions

  at 12 month and 24 month

• Describe the proportion of recurrence of anal lesions

  at 12 month and 24 month

• Prevalence of HPV infections

  at Day 0

Other Outcomes (5)

• Prevalence of others STIs : N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis, Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C

  At Day 0, at 12 month and 24 month

• Incidence of others STIs : Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis and Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C

  At Day 0, at 12 month and 24 month

• Determination of different Chlamydia trachomatis strains

  At Day 0

Interventions

STIs screening and care OTHER

* Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV). * Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM.

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Male who have sex with men living with HIV or not

You may qualify if:

• Being a male aged 18 or over
• Self-reporting as being a MSM
• Wishing to be part of a regular clinical follow-up
• Agreeing to participate in the study and signing the informed consent form
• Live in Lomé
• Regardless of HIV status (infected or not)
• Whether or not the participant has already taken antiretrovirals

You may not qualify if:

• Participation in another biomedical and/or behavioural study on HIV, viral hepatitis or sexually transmitted infections (CohMSM ANRS 12324-EF cohort of Lomé)

Sponsors & Collaborators

• ANRS, Emerging Infectious Diseases: lead
• Université de Lomé, Département de Santé Publique, Lomé, Togo: collaborator
• Bichat Hospital: collaborator
• Espoir Vie-Togo - ONG: collaborator
• Centre Africain de Recherche en Epidémiologie et en Santé Publique, Lomé, Togo: collaborator
• Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire: collaborator
• Laboratoire de Biologie Moléculaire et d'Immunologie, Lomé, Togo: collaborator
• Saint-Louis Hospital, Paris, France: collaborator
• University Hospital, Bordeaux: collaborator

Study Sites (1)

ONG, Espoir Vie Togo

Lomé, Togo

RECRUITING

Related Publications (1)

• Ferre VM, Sadio AJ, Gbeasor-Komlanvi FA, Bucau M, Salou M, Bercot B, Bebear C, Abramowitz L, Zaidi M, Amenyah-Ehlan AP, Mensah E, Braille A, Couvelard A, Dagnra AC, Ghosn J, Descamps D, Charpentier C, Ekouevi DK. High prevalence of bacterial STI, anal HPV, cytological abnormalities and anal lesions among MSM in Togo, 2021: a baseline analysis of the ANRS I MIE 12,400/DepIST-H cohort. BMC Infect Dis. 2025 Sep 26;25(1):1156. doi: 10.1186/s12879-025-11338-y.

  PMID: 41013315 DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

Urine, Blood Anal smear pharyngeal and oral specimens urethral specimens Swab of herpes vesicles

MeSH Terms

Conditions

Papillomavirus Infections; HIV Infections

Condition Hierarchy (Ancestors)

Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Communicable Diseases; Infections; DNA Virus Infections; Virus Diseases; Tumor Virus Infections; Genital Diseases; Urogenital Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Blood-Borne Infections; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Charlotte Charpentier

  Hôpital Bichat Claude Bernard, Paris, France

  PRINCIPAL INVESTIGATOR

• Didier Ekouevi

  Lomé University, Togo

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Didier Koumavi Ekouevi

CONTACT

+228 99 68 67 35; didier.ekouevi@gmail.com

Arnold Sadio

CONTACT

sadioarnold@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 22, 2020
• First Posted: June 2, 2021
• Study Start: June 24, 2021
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2024
• Last Updated: February 16, 2022

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share

Locations

TO (1)